377 related articles for article (PubMed ID: 38512448)
21. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
22. Current challenges in designing GBM trials for immunotherapy.
Weathers SP; Gilbert MR
J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
[TBL] [Abstract][Full Text] [Related]
23. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
24. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
26. Immunological Aspects of Malignant Gliomas.
Cohen-Inbar O; Zaaroor M
Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
[TBL] [Abstract][Full Text] [Related]
27. Vaccine-based immunotherapy for glioblastoma.
Thomas AA; Fisher JL; Ernstoff MS; Fadul CE
CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578
[TBL] [Abstract][Full Text] [Related]
28. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
29. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
[TBL] [Abstract][Full Text] [Related]
30. DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
[TBL] [Abstract][Full Text] [Related]
31. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
32. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
Genoud V; Migliorini D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
[TBL] [Abstract][Full Text] [Related]
33. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.
Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H
Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167
[TBL] [Abstract][Full Text] [Related]
34. Current vaccine trials in glioblastoma: a review.
Xu LW; Chow KK; Lim M; Li G
J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
[TBL] [Abstract][Full Text] [Related]
35. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
[TBL] [Abstract][Full Text] [Related]
36. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
[TBL] [Abstract][Full Text] [Related]
37. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Swartz AM; Li QJ; Sampson JH
Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
39. Promising vaccines for treating glioblastoma.
Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
[TBL] [Abstract][Full Text] [Related]
40. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
